Houston Healthspan Innovation Group
Houston Healthspan Innovation Group is a Houston-based life-sciences accelerator that provides lab facilities, multidisciplinary expertise, and commercialization support to early-stage companies focused on regenerative medicine and immune-restoration therapies. The organization offers laboratory space (including cleanrooms and cGMP cell culture workstations), access to technical and regulatory expertise, and services to support preclinical research, process development, small-scale biologics manufacturing, and clinical translation.
Industries
Nr. of Employees
medium (51-250)
Products
Rejenevie™ Therapeutics
A therapy that resets the immune system to enhance infection and cancer cell-killing while reducing inflammatory cells.
Stem Cell Isolation Devices and Consumables
Tools and materials used to isolate stem cells for regenerative medicine applications.
Regenerative Medicine Therapies
Therapeutic approaches aimed at repairing or regenerating damaged tissues using biological methods.
Healing Amplification Solutions
Technologies designed to enhance the body's natural healing processes.
Joint Ventures and Partnerships in Regenerative Medicine
Collaborative business arrangements to develop and commercialize regenerative medicine technologies and therapies.
Rejenevie™ Therapeutics
A therapy that resets the immune system to enhance infection and cancer cell-killing while reducing inflammatory cells.
Stem Cell Isolation Devices and Consumables
Tools and materials used to isolate stem cells for regenerative medicine applications.
Regenerative Medicine Therapies
Therapeutic approaches aimed at repairing or regenerating damaged tissues using biological methods.
Healing Amplification Solutions
Technologies designed to enhance the body's natural healing processes.
Joint Ventures and Partnerships in Regenerative Medicine
Collaborative business arrangements to develop and commercialize regenerative medicine technologies and therapies.
Services
Business development, mentorship, and operational support for early-stage life-science companies.
On-site lab space with cleanrooms and cell culture workstations to support preclinical research, process development and small-scale manufacturing.
Analytical testing and preclinical study support for regenerative medicine and cell therapy programs.
Support for regulatory strategy, IND-enabling study organization, and clinical trial planning based on in-house scientific and regulatory expertise.
Advisory and transactional support for forming joint ventures, partnerships and strategies to commercialize technologies.
Business development, mentorship, and operational support for early-stage life-science companies.
On-site lab space with cleanrooms and cell culture workstations to support preclinical research, process development and small-scale manufacturing.
Analytical testing and preclinical study support for regenerative medicine and cell therapy programs.
Support for regulatory strategy, IND-enabling study organization, and clinical trial planning based on in-house scientific and regulatory expertise.
Advisory and transactional support for forming joint ventures, partnerships and strategies to commercialize technologies.
Expertise Areas
- Regenerative medicine
- Cell therapy manufacturing and bioprocessing
- Clinical trial facilitation and translational medicine
- Regulatory strategy and IND-enabling studies
Key Technologies
- Automated enzymatic adipose-derived stem cell isolation
- Point-of-care cell processing systems
- cGMP cell culture workstations
- Cleanroom facilities for cell manufacturing
News & Updates
Press release announcing the launch of the Houston-based accelerator, its mission, lab facilities and initial client companies.
Announcement describing a first clinical application of an automated, fully enclosed cell isolation system that produced higher yields of stem cells from adipose tissue.
Announcement regarding the commencement of a Phase Ib clinical trial for an immune restoration therapy targeting age-related immune decline.
Press release announcing the launch of the Houston-based accelerator, its mission, lab facilities and initial client companies.
Announcement describing a first clinical application of an automated, fully enclosed cell isolation system that produced higher yields of stem cells from adipose tissue.
Announcement regarding the commencement of a Phase Ib clinical trial for an immune restoration therapy targeting age-related immune decline.